WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore, and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. 

About WuXi Vaccines

WuXi Vaccines, a joint venture of WuXi Biologics (stock code: 2269.HK) and Hile Bio-technology (stock code: 603718.SH), is primarily engaged in human vaccine (e.g. cancer vaccine) Contract Development and Manufacturing Organization (CDMO) business and provision of end-to-end integrated service and solution platform covering the discovery, development and manufacturing of vaccine from concept to commercial manufacturing.